Translate page

Hjort Hansen EHA 2019

Safety of Tyrosine Kinase Inhibitors (TKI's) in CML
Professor Henrik Hjorth-Hansen, Norwegian University of Science and Technology, Trondheim, Norway 

  • Patient Case with Treatment Courses on IM, DAS, NIL, and BOS
  • Overview of TKI side effects and management
    • Imatinib side effects - IRIS trial
    • Dasatinib - what to expect?
    • Pleural effusions - what to do?
    • Nilotinib - what to expect and what to do?
    • Cardiovascular risk determiniation
    • Bosuntinib - what to expect?
  • Patient case with treatment courses on IM, DAS, NIL and BOS
  • Practical advice


This talk was first presented during the Education Session on Chronic Myeloid Leukemia at EHA. You will find more education materials from EHA at the EHA Learning Centre